At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of Subcutaneous and Intravenous ALXN1820 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating ALXN1820 SC, ALXN1820 IV, and 2 other interventions for Healthy. Completed, enrolled 66 participants across 3 sites in 2 countries.
Detailed Summary
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1820 administered subcutaneously (SC) (ALXN1820 SC) and intravenously (IV) (ALXN1820 IV).
Study Details
Timeline
Interventions
ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
ALXN1820 IV (450 mg) will be administered as an IV infusion.
Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
Placebo IV will be administered as an IV infusion.